DuPont’s focused specialty-materials portfolio, 24.6% EBITDA margin, and secular water and healthcare tailwinds support upside, but PFAS liabilities remain the key discount and execution risk.
DuPont de Nemours, Inc. (NYSE: DD) represents a streamlined specialty materials provider following a multi-year portfolio transformation [cite: 1, 2]. Having completed the tax-free spin-off of its Electronics business (Qnity Electronics, Inc.) in November 2025 [cite: 2, 3] and the divestiture of its Aramids business in April 2026 for $1.8 billion in gross consideration [cite: 3, 4, 5], DuPont has shed legacy commodity volatility to concentrate on high-margin, innovation-driven end markets [cite: 2, 6]. Effective July 31, 2026, the company’s Global Industry Classification Standard (GICS) sector was updated to Industrials, reflecting its structural evolution into a high-value industrial technology platform [cite: 7].
The company generates revenue by selling engineered materials, specialized components, and advanced separation systems to customers across global industrial, healthcare, construction, and water management markets [cite: 1, 2, 8]. Following its segment realignment, operations are organized into two primary reportable segments [cite: 2, 9]:
* Healthcare & Water Technologies: Comprising approximately 47% of net sales, this segment provides biopharma tubing, medical packaging, personal protection solutions, and water filtration membranes (e.g., FilmTec reverse osmosis) [cite: 2, 4, 7].
* Diversified Industrials: Comprising approximately 53% of net sales, this segment focuses on Building Technologies and Industrial Technologies, delivering high-performance shelter systems (e.g., Tyvek), structural adhesives, and safety solutions [cite: 2, 4, 7, 9].
Geographically, DuPont maintains a global operational footprint spanning approximately 50 countries [cite: 9]. On a continuing operations basis, international markets generate approximately 53% of net sales (led by Asia Pacific and Europe, Middle East, and Africa [EMEA]), while North America accounts for the remaining 47% [cite: 9, 10].
DuPont's primary customer types include original equipment manufacturers (OEMs), pharmaceutical manufacturers, municipal water utilities, commercial construction contractors, and global industrial system integrators [cite: 1, 2, 7]. Customers select DuPont over market alternatives due to its proprietary product formulations, rigorous regulatory certifications in medical and water infrastructure, deep application engineering expertise, and critical brand reliance (e.g., Tyvek, FilmTec) [cite: 1, 7, 8, 11]. These core capabilities generate significant switching costs and pricing power in mission-critical applications where material failure carries substantial operational risks [cite: 8].
| Operating Metric / Attribute | Primary Details & Profile |
|---|---|
| GICS Sector Classification | Industrials (effective July 31, 2026) [cite: 7] |
| Reportable Segments | Healthcare & Water Technologies (47%); Diversified Industrials (53%) [cite: 2] |
| Geographic Mix | International (53%); North America (47%) [cite: 9, 10] |
| Key Legacy Actions | Qnity Electronics Spin-Off (Nov 2025); Aramids Divestiture ($1.8B, Apr 2026); 1-for-3 Reverse Split (June 2026) [cite: 3, 4, 5] |
| Core Value Drivers | Proprietary material formulations, regulatory certifications, high switching costs [cite: 8, 11] |
DuPont operates a highly specialized product portfolio structured across two main divisions: Healthcare & Water Technologies, which generates 47% of net sales, and Diversified Industrials, which generates 53% of net sales [cite: 2, 9].
In the Healthcare & Water Technologies division, Healthcare Technologies produces medical-grade silicone tubing, specialty fluid processing assemblies, biopharma single-use components, and Tyvek medical packaging [cite: 7, 12]. These products ensure sterile fluid transfer, pathogen barrier protection, and long-term shelf stability for medical devices and biologic drugs [cite: 7, 12]. Water Technologies manufactures reverse osmosis (RO) membranes, ultrafiltration systems, ion exchange resins, and nanofiltration elements under the FilmTec and Memtech brands [cite: 7, 10]. These systems serve municipal water purification, industrial wastewater reuse, and seawater desalination facilities [cite: 7, 13].
In the Diversified Industrials division, Building Technologies delivers weatherization barriers, weather-resistant membranes, commercial insulation, and building envelope systems anchored by the Tyvek product family [cite: 2, 7, 11]. Industrial Technologies provides specialized adhesives (such as structural adhesives for automotive and electric vehicle battery assemblies), thermal management materials, and protective industrial garments [cite: 1, 4, 6, 9].
DuPont possesses a durable economic moat built on four core pillars:
* High Switching Costs: In healthcare and biopharma, DuPont’s materials are specified directly into FDA-approved drug manufacturing protocols and medical device master files [cite: 7]. Changing material suppliers requires costly, multi-year regulatory re-validations for healthcare clients [cite: 7]. Similarly, municipal and industrial water treatment facilities are designed around specific membrane dimensions and pressure parameters, creating long-term lock-in for FilmTec replacement modules [cite: 7].
* Intellectual Property (IP) Advantage: DuPont holds approximately 4,700 active patents and patent applications globally tied to its continuing operations, with over 70% carrying a remaining term exceeding 5 years [cite: 9]. This IP portfolio covers specialized chemical syntheses, advanced membrane geometry, and barrier material laminations [cite: 7, 9, 11].
* Brand Power: Premium offerings like Tyvek and FilmTec hold leading market positions and command pricing premiums over generic alternatives due to decades of demonstrated reliability in extreme operating environments [cite: 7, 8, 11].
* Global Scale & Distribution Footprint: Operating across 50 countries with established regional technical support facilities creates high barriers to entry for smaller chemical producers attempting to serve global corporate clients [cite: 9].
The secular end markets underlying DuPont’s core segments benefit from durable long-term tailwinds. Driven by global water scarcity, industrial liquid zero-discharge mandates, and municipal infrastructure upgrades, the addressable global water treatment market is expanding at a 6% to 8% compound annual growth rate (CAGR) [cite: 4, 7]. Supported by expanding biologic drug pipelines and stringent international sterilization standards, healthcare materials markets are projected to grow at a 5% to 7% CAGR [cite: 7, 12]. Additionally, modernized energy-efficient building codes continue to boost demand for advanced shelter systems and building envelopes [cite: 2, 7, 11].
DuPont competes with specialty materials and industrial technology providers across its primary divisions [cite: 9, 14]. In Healthcare & Water, primary peers include Ecolab (Nalco Water), Veolia Environment, Danaher (Pall Corp), Toray Industries, and Entegris [cite: 13, 14]. In Diversified Industrials, main competitors include 3M Company, Arkema, Henkel, Sika AG, and Owens Corning [cite: 2, 14]. DuPont maintains market leadership in membrane-based water separation and medical packaging [cite: 7, 8, 12]. Following the divestiture of its lower-margin industrial assets and the spin-off of Electronics, management’s operational focus ("80/20" initiative) has targeted high-margin product lines to expand Operating EBITDA margins toward 25% [cite: 2, 4].
| Segment | Primary Brands | Key End Markets | Main Competitors | Position relative to Peers |
|---|---|---|---|---|
| Healthcare & Water Technologies | FilmTec, Memtech, Liveo | Biopharma, Municipal/Industrial Water, Healthcare | Ecolab, Veolia, Toray, Danaher | Market Leader in RO membranes & medical barrier packaging [cite: 7, 10, 13] |
| Diversified Industrials | Tyvek, Great Stuff, BETAMATE | Residential & Commercial Building, EV Adhesives | 3M, Sika AG, Henkel, Owens Corning | Strong competitive position in shelter systems & structural adhesives [cite: 4, 7, 11, 14] |
DuPont reported its Q2 2026 financial results on August 4, 2026 [cite: 4, 7, 15]. Financial performance demonstrated top-line stabilization and margin expansion following the recent corporate portfolio restructuring [cite: 2, 4, 7]. Net sales reached $1.819 billion, an increase of 4.0% year-over-year (4.0% organic growth) [cite: 4, 7]. Top-line growth was supported by a 4% organic increase in Healthcare & Water Technologies and a 3% organic increase in Diversified Industrials [cite: 4, 7]. GAAP Income from continuing operations reached $191 million, up significantly from $24 million in Q2 2025 [cite: 5, 7]. Operating EBITDA rose 8% year-over-year to $448 million, yielding an Operating EBITDA margin of 24.6% (expanding 40 to 80 basis points year-over-year) [cite: 4, 7]. Adjusted EPS printed at $1.88 per diluted share, representing a 48% increase from $1.27 in Q2 2025 [cite: 4, 7].
Adjusted EPS of $1.88 beat consensus analyst estimates of $1.76 to $1.81 per share by approximately 3.8% to 5.0% [cite: 6, 15, 16, 17]. Net sales of $1.819 billion slightly exceeded expectations of $1.81 billion [cite: 16]. Cash provided by operating activities from continuing operations reached $400 million, while transaction-adjusted free cash flow was $326 million, converting at 127% of adjusted net income [cite: 4, 7].
In Healthcare & Water Technologies, Q2 2026 net sales were $856 million, up 4% organically year-over-year [cite: 2, 4, 7]. Healthcare Technologies saw mid-single-digit organic growth driven by personal protection and biopharma demand [cite: 7]. Operating EBITDA margin for the segment stood at 30.1% [cite: 4, 7]. In Diversified Industrials, net sales were $963 million, up 3% organically year-over-year [cite: 2, 4, 7]. Building Technologies recorded low-single-digit organic growth amid initial signs of housing market recovery in Asia Pacific and residential construction in North America [cite: 2, 7]. Operating EBITDA margin was 22.1% (up 70 bps year-over-year) [cite: 7].
Management updated full-year 2026 guidance during the Q2 release [cite: 4, 7]. Full-year 2026 net sales guidance was raised to $7.16 billion – $7.19 billion (midpoint $7.175 billion), implying organic growth slightly above 4% [cite: 4, 7]. Operating EBITDA guidance was raised to a midpoint of $1.76 billion, with expected margins around 24.5% [cite: 4, 7]. Adjusted EPS guidance was raised to $7.17 – $7.32 (midpoint $7.24), representing an 18% year-over-year increase [cite: 4, 7]. Organic sales growth is projected to accelerate to ~6% year-over-year in the second half of 2026, supported by Q3 2026 net sales guidance of $1.835 billion and Adjusted EPS of $1.80 to $1.90 [cite: 4].
Management noted that organic growth expectations for the Water business were adjusted to a low-to-mid single-digit range due to timing volatility on large project installations in the Middle East [cite: 4, 16]. Management also highlighted the execution of its "80/20" operational workflow, net productivity initiatives, and the ongoing rollout of sustainable material innovations like lower-carbon Tyvek [cite: 4, 11].
Despite bottom-line and top-line quarterly beats alongside raised full-year guidance, DuPont’s stock fell approximately 1.1% to 6.25% in immediate trading following the announcement [cite: 6, 16, 17]. Market participants anchored on the lowered near-term organic growth target in the Water segment caused by Middle East project delays, as well as broader macroeconomic pressure across cyclical industrial stocks [cite: 16].
| Metric | Q2 2026 Actual | Q2 2025 Actual | YoY Change | Wall St. Estimate | Performance vs. Consensus |
|---|---|---|---|---|---|
| Net Sales ($B) | $1.819 | $1.749 | +4.0% | $1.810 | Beat (+0.5%) [cite: 4, 7, 16] |
| Operating EBITDA ($M) | $448 | $423 | +5.9% | $435 | Beat (+3.0%) [cite: 4, 7] |
| EBITDA Margin (%) | 24.6% | 24.2% | +40 bps | 24.0% | Expansion (+60 bps) [cite: 4, 7] |
| Adjusted EPS ($) | $1.88 | $1.27 | +48.0% | $1.76 - $1.81 | Beat (+3.8% to +6.8%) [cite: 4, 15, 16, 17] |
| Free Cash Flow ($M) | $326 | $107 | +204.7% | N/A | Strong Conversion (127%) [cite: 4, 7] |
As of June 30, 2026, DuPont held $1.740 billion in cash and cash equivalents against $3.125 billion in long-term debt, yielding a net debt position of $1.385 billion [cite: 5, 7, 18]. Long-term debt-to-equity stands at a conservative ratio of 0.23x [cite: 18]. Capital allocation priorities remain focused on organic innovation, selective bolt-on M&A (such as the Sinochem RO Memtech acquisition) [cite: 10, 11], disciplined dividend growth ($0.60 quarterly per post-split share, or $2.40 annualized, yielding ~1.8%) [cite: 11, 16, 18, 19], and opportunistic share buybacks (authorized a new $250 million share buyback in Q3 2026 following prior Accelerated Share Repurchase programs) [cite: 2, 7, 20].
Trading at approximately $129.34 to $133.95 per share with an equity market capitalization of ~$18.1 billion (reflecting the 1-for-3 reverse stock split in June 2026) [cite: 4, 5, 8, 11, 19], DuPont trades at ~18.2x FY 2026 Price-to-Adjusted EPS (based on midpoint $7.24 Adj EPS guidance) [cite: 4, 7] and ~11.1x EV / FY 2026 Operating EBITDA (based on Enterprise Value of ~$19.5 billion and guidance EBITDA midpoint of $1.76 billion) [cite: 4, 7, 8]. On a Price / Sales (TTM) basis, shares trade at ~2.5x to 2.6x on post-split continuing sales [cite: 16, 18]. This valuation represents a discount to legacy specialty peers (which trade at 20x-22x forward earnings), primarily reflecting market caution surrounding unresolved legacy environmental indemnification liabilities [cite: 16].
DuPont is managing a multi-stage corporate restructuring [cite: 2, 3]. Execution risks include potential cost dis-synergies following the Electronics (Qnity) spin-off and Aramids divestiture [cite: 2, 3], as well as potential delays in operational "80/20" cost productivity programs designed to permanently lower overhead [cite: 4, 20]. Failure to hit net productivity targets could squeeze segment margins if volumes stall [cite: 2, 4].
The primary risk overhang facing DuPont stems from legacy per- and polyfluoroalkyl substances (PFAS) litigation and environmental liabilities [cite: 5, 11, 16]. Under a Memorandum of Understanding (MoU) with Chemours and Corteva, DuPont shares liabilities associated with historical chemical manufacturing activities [cite: 5, 11]. As of June 30, 2026, accrued indemnification liabilities under this framework were $530 million, including a $188 million accrual for a proposed $875 million New Jersey settlement and $125 million related to North Carolina claims (settled in September 2026 for $455 million shared among the parties) [cite: 5, 11, 16]. Ongoing lawsuits from municipal water districts, state attorneys general (e.g., New York), and private plaintiffs (e.g., firefighter suits) present uncertainty regarding potential cash outlays [cite: 1, 5, 11].
While DuPont’s customer base is diversified, demand within Diversified Industrials depends on global residential and commercial construction cycles [cite: 2, 7, 8]. Higher interest rates or persistent weakness in European and Asian construction markets could delay orders for Tyvek and building solutions [cite: 7, 8, 16]. In Water Technologies, large municipal projects in the Middle East and developing markets are subject to political timing and budget deferrals [cite: 4, 16].
With 53% of net sales derived from international operations, earnings are exposed to foreign currency translation volatility, primarily against the European Euro, Chinese Renminbi, and Japanese Yen [cite: 9, 21]. Moreover, persistent global inflation in raw material inputs or energy costs could compress operating margins if price adjustments cannot be passed through quickly to industrial buyers [cite: 9, 16].
A major economic downturn occurring simultaneously with unexpected adverse rulings or larger-than-expected cash settlements in PFAS litigation represents the worst-case operating scenario [cite: 11, 16]. Early warning signs of fundamental deterioration would include sequentially declining organic volumes in Healthcare & Water Technologies, widening gross margin compression, or upward revisions to legal reserve accruals in quarterly filings [cite: 4, 5, 8, 18]. Key thesis breakers would consist of persistent loss of market share in core membrane separation technologies or a multi-billion dollar escalation in PFAS litigation obligations that breaches current indemnity caps and impairs the balance sheet [cite: 5, 9, 11, 16].
The following 5-year scenario analysis models DuPont’s share price trajectory through FY 2031 (Year 5) based on post-reverse split capital structure metrics (~135.04 million basic shares outstanding as of mid-2026) [cite: 5, 20]. Model inputs assume a starting share price of $133.00 USD (as of October 2026) [cite: 8, 19] and baseline FY 2026 guidance midpoints of $7.175 billion in revenue, $1.760 billion in Operating EBITDA (24.5% margin), and $7.24 in Adjusted EPS [cite: 4, 7]. Share count evolution reflects annual share repurchases funded by organic free cash flow [cite: 2, 7].
In the Base Case scenario (60% probability weight), organic sales grow at a 4.5% CAGR over 5 years, reaching $8.95 billion by FY 2031 [cite: 4, 7]. Growth is driven by steady adoption of biopharma single-use solutions, water membrane demand, and a recovery in building construction [cite: 2, 4, 7]. Operating EBITDA margin expands to 26.5% ($2.37 billion) as "80/20" productivity initiatives take full effect [cite: 4, 7]. Net margin reaches 16.0%, yielding FY 2031 Net Income of $1.43 billion. Share repurchases reduce outstanding diluted share count from ~136.8 million to 134.0 million [cite: 7], pushing Adjusted EPS to $10.65 per share. An exit P/E multiple of 17.5x applied to FY 2031 EPS yields an implied share price of $186.38 USD. Adding cumulative 5-year dividends of $13.50 USD results in a total return value of $199.88 USD, delivering a 50.3% total return (8.5% annualized).
In the High Case scenario (20% probability weight), accelerated global investments in water infrastructure and biopharma demand drive a 7.0% revenue CAGR, pushing FY 2031 revenue to $10.06 billion [cite: 4, 7]. EBITDA margins expand to 29.0% ($2.92 billion) due to pricing power and favorable product mix [cite: 4, 7]. FY 2031 Net Income reaches $1.84 billion. Aggressive share repurchases trim diluted share count to 130.0 million, resulting in Adjusted EPS of $14.15 per share. Resolution of PFAS legal overhang allows the stock to re-rate to a specialty chemical P/E multiple of 21.0x, yielding an implied share price of $297.15 USD. Including $15.00 USD in cumulative dividends, total return value reaches $312.15 USD, delivering a 134.7% total return (18.6% annualized).
In the Low Case scenario (20% probability weight), macro stagnation and construction weakness restrict revenue growth to a 1.5% CAGR, yielding FY 2031 sales of $7.72 billion [cite: 7, 16]. Operating EBITDA margin contracts to 21.5% ($1.66 billion) due to raw material inflation and lack of operating leverage [cite: 9, 16]. Net Income falls to $810 million, while share repurchases stall, leaving share count at 132.8 million and Adjusted EPS at $6.10 per share. Continued PFAS litigation uncertainty suppresses valuation to a P/E multiple of 12.0x, resulting in an implied share price of $73.20 USD. Including $12.00 USD in cumulative dividends, total return value is $85.20 USD, resulting in a total return of -35.9% (-8.5% annualized).
The probability-weighted implied 5-year share price is calculated as $(0.60 \times 186.38) + (0.20 \times 297.15) + (0.20 \times 73.20) = \$111.83 + \$59.43 + \$14.64 = \mathbf{\$185.90}$ USD. Relative to the current share price of $133.00 USD, this indicates an implied probability-weighted share price upside of 39.8%.
| Scenario | Revenue in Year 5 (FY31) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price | Implied Future Share Price | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $10.06 Billion | 29.0% EBITDA Margin / $14.15 EPS | 21.0x Exit P/E | $133.00 USD | $297.15 USD | +134.7% | +18.6% | 20% |
| Base Case | $8.95 Billion | 26.5% EBITDA Margin / $10.65 EPS | 17.5x Exit P/E | $133.00 USD | $186.38 USD | +50.3% | +8.5% | 60% |
| Low Case | $7.72 Billion | 21.5% EBITDA Margin / $6.10 EPS | 12.0x Exit P/E | $133.00 USD | $73.20 USD | -35.9% | -8.5% | 20% |
| Weighted Average | -- | -- | -- | $133.00 USD | $185.90 USD | +39.8% | +6.9% | 100% |
COMPOUNDING SPECIALTY VALUE
Management alignment rates at 8/10. Executive incentives are tied to operational performance, with CEO Lori Koch and senior leadership compensated based on organic revenue growth, Operating EBITDA margin expansion, and return on invested capital (ROIC) [cite: 22, 23]. Executive stock ownership guidelines reinforce alignment with long-term investors [cite: 9, 22].
Revenue quality scores 8/10. Revenue streams are supported by proprietary product specifications in regulated markets like biopharma and municipal water treatment [cite: 7]. Recurring sales of replacement filtration membranes and biopharma tubing reduce overall top-line volatility [cite: 4, 7].
Market position scores 9/10. DuPont holds leading global positions in membrane water filtration (FilmTec) and protective medical packaging (Tyvek) [cite: 7, 11, 13]. These established brand profiles create meaningful entry barriers [cite: 8, 11].
Growth outlook scores 7/10. Exposure to long-term tailwinds in water treatment and healthcare supports steady growth [cite: 4, 7]. However, cyclical sensitivity in residential and commercial construction within Diversified Industrials partially tempers top-line expansion [cite: 2, 7, 16].
Financial health rates at 8/10. Conservative financial leverage, characterized by $3.125 billion in long-term debt against $1.740 billion in cash and cash equivalents (0.23x Debt-to-Equity), provides financial flexibility [cite: 5, 7, 18]. Free cash flow conversion remains disciplined (127% conversion in Q2 2026) [cite: 4, 7].
Business viability rates at 8/10. Proprietary formulations and deep integration into customer manufacturing workflows support durable business viability [cite: 7, 8]. Primary operational choke points center on key raw material supply chains for specialized polymers and silicones [cite: 7, 9].
Capital allocation scores 8/10. Management has actively reshaped the corporate footprint by exiting commodity-exposed divisions (Electronics spin, Aramids sale) to reallocate capital into higher-margin growth platforms [cite: 2, 3, 4, 5]. Share buybacks ($250 million authorized in Q3 2026) and cash dividends supplement capital returns [cite: 2, 7, 11, 16].
Analyst sentiment rates at 8/10. Sell-side sentiment remains positive, with approximately 75% of covering equity research analysts maintaining positive ratings due to structural portfolio enhancements [cite: 1, 8, 24].
Profitability rates at 8/10. Operating EBITDA margins of 24.6% in Q2 2026 demonstrate pricing power and effective overhead management under the company's "80/20" operational simplified workflow [cite: 4, 7].
Track record scores 6/10. Although recent operational execution has been disciplined, multi-year portfolio restructuring and lingering PFAS legal liabilities have historically weighed on overall total shareholder returns [cite: 2, 11, 16].
The resulting overall blended qualitative score is 7.7 / 10.
DISCIPLINED OPERATIONAL TRANSFORMATION
DuPont de Nemours, Inc. presents a streamlined operational profile centered on specialized material science applications [cite: 1, 2]. Following the separation of its Electronics platform and the divestiture of its Aramids division, the remaining business offers greater operational focus, higher cash conversion, and reduced cyclical commodity exposure [cite: 2, 3, 4, 7].
The core thesis rests on four structural pillars:
1. Portfolio Simplification: Operating as a high-margin industrial technology provider focused on Healthcare & Water Technologies and Diversified Industrials supports Operating EBITDA margin expansion toward 25%-26% [cite: 2, 4, 7, 9].
2. Secular End-Market Growth: Aligned with long-term global investments in water purification, biopharma processing, and energy-efficient building materials [cite: 4, 7, 11].
3. Disciplined Free Cash Flow Conversion: Strong free cash flow generation (127% conversion in Q2 2026) supports ongoing share buybacks ($250 million authorized in Q3 2026) and a stable dividend yield [cite: 2, 4, 7, 11, 16].
4. Litigation Resolution: Progress in addressing legacy PFAS claims under the Memorandum of Understanding with Chemours and Corteva provides improved visibility into long-term cash obligations, facilitating potential equity multiple expansion [cite: 5, 11, 16].
Key risk factors to monitor include potential expansion of legacy PFAS legal liabilities beyond current accrued reserves ($530 million as of Q2 2026) [cite: 5, 11, 16], macroeconomic softness in commercial construction [cite: 7, 16], and foreign currency exchange volatility across international markets [cite: 9, 10].
HIGH-QUALITY SPECIALTY RESTRUCTURING
DuPont’s stock has recently traded between $129.34 and $138.99, sitting slightly below its 200-day moving average (located in the low $140s) while holding technical support near $132.04 [cite: 8, 19, 25]. The stock experienced a minor pullback following its Q2 2026 earnings release as investors focused on project timing delays in Middle East water markets despite top- and bottom-line quarterly beats [cite: 6, 16, 17]. Recent progress on legal settlements, including the September 2026 North Carolina PFAS agreement, has helped stabilize sentiment [cite: 11, 16]. In the near term, shares appear likely to consolidate between $130 and $142 as the market evaluates second-half organic growth execution and broader industrial market trends [cite: 4, 16, 25].
NEAR-TERM CONSOLIDATION PHASE
View DuPont de Nemours, Inc. (DD) stock page
Loading the interactive version of this report…